Hexarelin Reconstitution Calculator

No. Hexarelin has human endocrine study data, but it does not have FDA-approved therapeutic use and is generally discussed as a non-approved GH secretagogue (human clinical studies). It is also prohibited in sport anti-doping contexts as part of the GH secretagogue class (analytical/regulatory).

Hexarelin is a ghrelin-receptor–acting GH secretagogue that increases GH release in humans, but unlike more selective agents it also tends to raise prolactin, ACTH, and cortisol (human mechanistic/endocrine studies). In repeated dosing, it increases 24-hour GH exposure, but the non-GH endocrine spillover is a defining feature and is one reason it is less “clean” than ipamorelin (human clinical studies/review).

Subcutaneous and IV are the most reliable if the goal is a strong GH pulse; intranasal and oral are biologically active in humans but less efficient (human pharmacodynamic studies). Early route-comparison work showed GH release after IV, SC, intranasal, and oral dosing, but potency fell substantially as delivery moved away from parenteral routes, so SC is the practical standard when used outside formal studies (human clinical studies). Community protocol: SC is usually preferred for consistency; intranasal/oral are rarely used now because of weaker and more variable effect.

Human dose-response work showed clear endocrine activity at low microgram-per-kilogram doses, with 2 μg/kg IV used repeatedly in several studies and dose-response demonstrated in the low μg/kg range (human clinical studies). Community protocol: common research-use ranges are 100–200 μg SC 1–2×/day, sometimes up to 3×/day, but higher frequency increases the chance of prolactin/cortisol elevation (community protocol; supported conceptually by 2–3 daily injection endocrine data).

Evidence for direct physique effects in humans is weak. What is documented is acute and repeated stimulation of GH secretion, not robust human data showing large increases in lean mass or reliable fat loss (human endocrine studies/review). Practically, Hexarelin is better viewed as a potent hormonal secretagogue than a proven body-composition drug. If used for physique goals, expectations should be modest, and endocrine side effects often become the limiting factor (human clinical studies).

For “cleaner” endocrine signaling, no. Hexarelin is potent for GH release, but it commonly increases ACTH/cortisol and prolactin, whereas ipamorelin is generally considered more selective and ACTH/cortisol-sparing; tesamorelin has the strongest formal human efficacy evidence overall, but in HIV-associated visceral adiposity rather than bodybuilding (human review and endocrine studies). So Hexarelin is usually chosen for potency, not selectivity or evidence quality.

The main recurring issues are prolactin elevation, ACTH/cortisol stimulation, and sleep architecture changes; one human sleep study found decreased slow-wave sleep along with increased GH, ACTH, cortisol, and prolactin during sleep (human clinical study). Based on the broader GH-secretagogue literature, users should also watch for edema, appetite changes, paresthesias, and dysglycemia, although Hexarelin-specific long-term safety data are limited (review/human endocrine extrapolation). Because repeated daily dosing can sustain endocrine stimulation, side-effect burden usually rises with frequency (human study).

There is no well-established long-term, modern safety protocol. Human studies include acute administration and repeated dosing paradigms, but the evidence base is not sufficient to define safe chronic use for physique or anti-aging purposes (human clinical studies/review). Community protocol: cycles are often kept short, around 4–8 weeks, to limit receptor adaptation and prolactin/cortisol burden. If someone is using it longer, monitoring IGF-1, fasting glucose, prolactin, and possibly AM cortisol is the practical minimum (practitioner consensus; evidence-informed by endocrine effects).

There are promising non-human data suggesting tissue-protective effects in heart, retina, kidney, lung, and other models, but this is preclinical and should not be confused with proven clinical efficacy in people (animal/preclinical). The compound appears biologically active outside the pituitary axis, but that research is not enough to justify confident human therapeutic claims yet (review + preclinical).

For competition: no, assume it is prohibited. GH secretagogues are within anti-doping detection programs and remain a testing target (regulatory/anti-doping). For travel: as a practical matter, peptide vials are usually carried with standard injectable supplies and temperature protection if needed (community protocol), but legality and customs risk depend on jurisdiction and prescription status.